Hitachi prepares response to FDA warning letter
A warning letter issued July 13 by the FDA to Hitachi Medical Systems of America has called into question the company’s reporting mechanism for patient injuries.
A warning letter issued July 13 by the FDA to Hitachi Medical Systems of America has called into question the company's reporting mechanism for patient injuries.
Deviations from FDA-required methods for handling such complaints were identified during an onsite audit conducted in April, according to Sheldon Schaffer, vice president and general manager of MR for the Japanese-owned subsidiary headquartered in Ohio.
"We owe the FDA a response regarding the warning letter and we will be doing so," he said. "The response will inform them of the corrective actions we have already taken and what we plan to complete in the next 30 days. We are looking forward to working with the FDA to close out the findings."
The letter to Hitachi, like many warning letters issued by the FDA, identified procedural problems related to the FDA's Quality System regulation, which requires manufacturers to maintain a system for ensuring quality in the design and production of medical devices distributed commercially in the U.S. Warning letters such as the one issued to Hitachi, which cited the FDA's MDR (medical device reporting) system, are designed to bring companies into compliance with reporting requirements. Such a move allows the watchdog agency to keep tabs on patient safety issues.
Incidents identified in the warning letter to Hitachi were among the information the FDA was reviewing as part of its April audit of the company. They include patient reports of headaches resulting from a head coil-related burn received during an MR scan, as well as tinnitus and hearing loss due to loud sounds during scanning.
Since being alerted of its noncompliance, the company has modified its MDR procedures to ensure that whenever one of its products could contribute to serious injuries, the incidents are properly reported to the FDA, Schaffer said. The company has also modified and enhanced its procedures for correcting products found to cause such potential injuries.
Only one issue remains, according to Schaffer. This relates to the process of reviewing, evaluating, and processing customer complaints.
"It is our plan and intention that all the concerns listed in the warning letter will be fully responded to by the end of August," he said.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
